Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14355 | ISIN: FI4000153309 | Ticker-Symbol: 4FR
Frankfurt
06.06.25 | 08:18
2,480 Euro
-7,64 % -0,205
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FARON PHARMACEUTICALS OY Chart 1 Jahr
5-Tage-Chart
FARON PHARMACEUTICALS OY 5-Tage-Chart
RealtimeGeldBriefZeit
2,5202,54517:30

Aktuelle News zur FARON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FARON PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoFaron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation174TURKU, FI / ACCESS Newswire / June 5, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies...
► Artikel lesen
DoFaron Pharma founders donate shares, sell stake3
DoGründer von Faron Pharma spenden Aktien und verkaufen Anteile3
DiFaron Pharmaceuticals erweitert Aktienanzahl durch neue Registrierung2
MoFaron Pharmaceuticals Presents Phase II Data from BEXMAB Study at ASCO 2025180TURKU, FI / ACCESS Newswire / June 2, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Favorable response rates and survival data in high/very high-risk frontline and r/r MDS support advancement...
► Artikel lesen
30.05.Faron Pharmaceuticals: Faron Announces Publication of Full Phase I BEXMAB Study Data in Lancet Haematology335TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in high-risk...
► Artikel lesen
27.05.Faron Pharmaceuticals stärkt Aktienflexibilität für Anleiheumwandlungen5
27.05.Faron Pharmaceuticals bolsters share flexibility for bond conversions4
27.05.Faron Pharmaceuticals: Faron's Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid Malignancies575TURKU, FI / ACCESS Newswire / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases...
► Artikel lesen
23.05.Faron Pharmaceuticals: Faron Announces New Data that Highlight Patient Populations with Cancer that are Most Likely to Benefit from First-in-class Immunotherapy Bexmarilimab263TURKU, FI / ACCESS Newswire / May 23, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New data published in the Journal for ImmunoTherapy of Cancerreveals how tumor microenvironment shapes response...
► Artikel lesen
21.05.IN BRIEF: Faron Pharmaceuticals appoints new chief business officer3
21.05.Faron Pharmaceuticals: Faron Appoints Ralph Hughes as Chief Business Officer260Ralph Hughes joins Faron to strengthen Commercial Strategy, Business Development and Market Assessment function TURKU, FI / ACCESS Newswire / May 21, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First...
► Artikel lesen
15.05.Faron Pharmaceuticals: Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress280TURKU, FI / ACCESS Newswire / May 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Overcoming immune resistance in HR-MDS: Detailed safety and efficacy Phase II data on bexmarilimab to be presented...
► Artikel lesen
14.05.Faron Pharmaceuticals Ltd: Grant of Options488TURKU, FINLAND / ACCESS Newswire / May 14, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN):Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused...
► Artikel lesen
14.05.Faron Pharmaceuticals gibt neue Mitarbeiteroptionen aus3
14.05.Faron Pharmaceuticals issues new employee options2
12.05.Faron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary Session627TURKU, FI / ACCESS Newswire / May 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact...
► Artikel lesen
24.04.Faron Pharmaceuticals: Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025285Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / ACCESS Newswire / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage...
► Artikel lesen
17.04.Faron Pharmaceuticals: Holding in Company271TURKU, FI / ACCESS Newswire / April 17, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies...
► Artikel lesen
15.04.Faron Pharmaceuticals: Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome705TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r...
► Artikel lesen
Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1